323 related articles for article (PubMed ID: 19135495)
1. Protection against Yersinia pseudotuberculosis infection conferred by a Lactococcus lactis mucosal delivery vector secreting LcrV.
Daniel C; Sebbane F; Poiret S; Goudercourt D; Dewulf J; Mullet C; Simonet M; Pot B
Vaccine; 2009 Feb; 27(8):1141-4. PubMed ID: 19135495
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the protective immune response to Yersinia pseudotuberculosis infection in mice vaccinated with an LcrV-secreting strain of Lactococcus lactis.
Daniel C; Titecat M; Poiret S; Cayet D; Boutillier D; Simonet M; Sirard JC; Lemaître N; Sebbane F
Vaccine; 2016 Nov; 34(47):5762-5767. PubMed ID: 27742220
[TBL] [Abstract][Full Text] [Related]
3. Polymorphism in the
Daniel C; Dewitte A; Poiret S; Marceau M; Simonet M; Marceau L; Descombes G; Boutillier D; Bennaceur N; Bontemps-Gallo S; Lemaître N; Sebbane F
Front Immunol; 2019; 10():1830. PubMed ID: 31428104
[TBL] [Abstract][Full Text] [Related]
4. A Recombinant Attenuated
Singh AK; Curtiss R; Sun W
Infect Immun; 2019 Oct; 87(10):. PubMed ID: 31331960
[TBL] [Abstract][Full Text] [Related]
5. Prevention and treatment of colitis with Lactococcus lactis secreting the immunomodulatory Yersinia LcrV protein.
Foligne B; Dessein R; Marceau M; Poiret S; Chamaillard M; Pot B; Simonet M; Daniel C
Gastroenterology; 2007 Sep; 133(3):862-74. PubMed ID: 17678918
[TBL] [Abstract][Full Text] [Related]
6. LcrV synthesis is altered by DNA adenine methylase overproduction in Yersinia pseudotuberculosis and is required to confer immunity in vaccinated hosts.
Badie G; Heithoff DM; Mahan MJ
Infect Immun; 2004 Nov; 72(11):6707-10. PubMed ID: 15501808
[TBL] [Abstract][Full Text] [Related]
7. Vaccine Potential of a Recombinant Bivalent Fusion Protein LcrV-HSP70 Against Plague and Yersiniosis.
Gupta A; Narayan B; Kumar S; Verma SK
Front Immunol; 2020; 11():988. PubMed ID: 32595634
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the Yersinia enterocolitica 0:8 V antigen for cross protectivity.
Schmidt A; Schaffelhofer S; Müller K; Röllinghoff M; Beuscher HU
Microb Pathog; 1999 Apr; 26(4):221-33. PubMed ID: 10089162
[TBL] [Abstract][Full Text] [Related]
9. YopE specific CD8+ T cells provide protection against systemic and mucosal Yersinia pseudotuberculosis infection.
González-Juarbe N; Shen H; Bergman MA; Orihuela CJ; Dube PH
PLoS One; 2017; 12(2):e0172314. PubMed ID: 28207901
[TBL] [Abstract][Full Text] [Related]
10. N255 is a key residue for recognition by a monoclonal antibody which protects against Yersinia pestis infection.
Hill J; Leary S; Smither S; Best A; Pettersson J; Forsberg A; Lingard B; Lipka A; Brown KA; Williamson ED; Titball RW
Vaccine; 2009 Nov; 27(50):7073-9. PubMed ID: 19786138
[TBL] [Abstract][Full Text] [Related]
11. CD8(+) T cells specific to a single Yersinia pseudotuberculosis epitope restrict bacterial replication in the liver but fail to provide sterilizing immunity.
Shen H; Gonzalez-Juarbe N; Blanchette K; Crimmins G; Bergman MA; Isberg RR; Orihuela CJ; Dube PH
Infect Genet Evol; 2016 Sep; 43():289-96. PubMed ID: 27268148
[TBL] [Abstract][Full Text] [Related]
12. LcrV delivered via type III secretion system of live attenuated Yersinia pseudotuberculosis enhances immunogenicity against pneumonic plague.
Sun W; Sanapala S; Henderson JC; Sam S; Olinzock J; Trent MS; Curtiss R
Infect Immun; 2014 Oct; 82(10):4390-404. PubMed ID: 25114109
[TBL] [Abstract][Full Text] [Related]
13. Mucosal co-immunization of mice with recombinant lactococci secreting VapA antigen and leptin elicits a protective immune response against Rhodococcus equi infection.
Cauchard S; Bermúdez-Humarán LG; Blugeon S; Laugier C; Langella P; Cauchard J
Vaccine; 2011 Dec; 30(1):95-102. PubMed ID: 22019740
[TBL] [Abstract][Full Text] [Related]
14. Oral vaccination with LcrV from Yersinia pestis KIM delivered by live attenuated Salmonella enterica serovar Typhimurium elicits a protective immune response against challenge with Yersinia pseudotuberculosis and Yersinia enterocolitica.
Branger CG; Torres-Escobar A; Sun W; Perry R; Fetherston J; Roland KL; Curtiss R
Vaccine; 2009 Aug; 27(39):5363-70. PubMed ID: 19596407
[TBL] [Abstract][Full Text] [Related]
15. Induction of antigen-specific immune responses by oral vaccination with Saccharomyces cerevisiae expressing Actinobacillus pleuropneumoniae ApxIIA.
Shin SJ; Bae JL; Cho YW; Lee DY; Kim DH; Yang MS; Jang YS; Yoo HS
FEMS Immunol Med Microbiol; 2005 Feb; 43(2):155-64. PubMed ID: 15681145
[TBL] [Abstract][Full Text] [Related]
16. Immunization with a DNA adenine methylase over-producing Yersinia pseudotuberculosis vaccine confers robust cross-protection against heterologous pathogenic serotypes.
Kubicek-Sutherland JZ; Heithoff DM; Ersoy SC; Shimp WR; Mahan MJ
Vaccine; 2014 Mar; 32(13):1451-9. PubMed ID: 24508035
[TBL] [Abstract][Full Text] [Related]
17. A recombinant bivalent fusion protein rVE confers active and passive protection against Yersinia enterocolitica infection in mice.
Singh AK; Kingston JJ; Murali HS; Batra HV
Vaccine; 2014 Mar; 32(11):1233-9. PubMed ID: 24486353
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of an oral live vaccine for veterinary use against pseudotuberculosis.
Quintard B; Petit T; Ruvoen N; Carniel E; Demeure CE
Comp Immunol Microbiol Infect Dis; 2010 Dec; 33(6):e59-65. PubMed ID: 20034670
[TBL] [Abstract][Full Text] [Related]
19. Influence of the route of immunization and the nature of the bacterial vector on immunogenicity of mucosal vaccines based on lactic acid bacteria.
Cortes-Perez NG; Lefèvre F; Corthier G; Adel-Patient K; Langella P; Bermúdez-Humarán LG
Vaccine; 2007 Sep; 25(36):6581-8. PubMed ID: 17675182
[TBL] [Abstract][Full Text] [Related]
20. Secretory expression of K88 (F4) fimbrial adhesin FaeG by recombinant Lactococcus lactis for oral vaccination and its protective immune response in mice.
Hu CX; Xu ZR; Li WF; Niu D; Lu P; Fu LL
Biotechnol Lett; 2009 Jul; 31(7):991-7. PubMed ID: 19277476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]